

17th NAME Meeting Program

Thursday					
Session Title	Chairs	Time allocated	Speaker	Title	
9:00-9:10	Welcome and thanks to sponsors		10 Phil Hansbro GSK representative AZeneca Chiesi	Welcome to country Introduction from sponsors Introduction to NAME17	
9:10-10:00	Asthma	45+5	Prof Maarten Van Den Berge	ATLANTIS small airways study and role of fixed airflow obstruction in asthma.	
10:00-10:30		25+5	Prof Ian Adcock	Microbial- and non-microbial-mediated neutrophilic asthma	
10:30-10:45		12+3	Dr Gesa Albers	Airway macrophage glycolysis controls lung homeostasis and responses to aeroallergen	
10:45-11:00		12+3	Dr Ridhima Wadhwa	Itaconate, a Krebs cycle intermediate reduces disease features in experimental asthma	
11.00-11.30 Morning Tea 30					
11.30-12.00	Interstitial lung diseases	25+5	Dr Shafagh Waters	Your Treatment, Your Organoid: Personalized Medicine for Rare Lung Diseases	
12.00-12.30		25+5	Dr Sionne Lucas	Rare variants in IPF families	
12.30-12.45		12+3	Dr Gang Liu	Mast cells regulates lung fibrosis in idiopathic pulmonary fibrosis	
12.45-1.00		12+3	Dr Wolfgang Jarolimek	Inhibitors of amine oxidases for the treatment of inflammation and fibrosis	
1.00-2.00 Lunch 60					
2.00-2.30	Infectious respiratory diseases	25+5	Prof Jon Iredell	Opportunities and challenges in the therapeutic use of bacteriophages	
2.30-3.00		25+5	Prof Peter Wark	RSV vaccination: challenges and approaches	
3.00-3.30		25+5	Prof Anthony Byrne	Post-TB and Post-COVID lung disease	
3.30-3.45		12+3	Prof Angelo Izzo	Tuberculosis vaccines: the good, the bad and the ...	
3.45-4.00		12+3	Dr Hung-Hsun Yen	Animal models for accessing efferent lymph draining the nose and lungs in real-time	
4.00-4.30 Afternoon Tea 30					
4.30-5.00 Poster Pitch Session 2min per person / one slide / rapid fire					
17:00-19:00 Poster session					
19.00 - late Dinner - Grandstand					
Friday					
Session Title	Chairs	Time allocated	Speaker	Title	
9:00-9:05	Welcome and thanks to sponsors		5 Phil Hansbro		
9.05-10.00	COPD	50+5	Prof Fernando Martinez	COPD 'early disease' biology, therapeutic implications and future therapeutic developments	
10.00-10.15		12+3	Dr Alen Faiz	IL-33 Expression Is Lower in Current Smokers at Both Transcriptomic and Protein Level	
10.15-10.30		12+3	Dr Shatarupa Das	Translating Murine Studies to Human Hope: Unveiling Novel Therapies for Chronic Obstructive Pulmonary Disease (COPD)	
10.30-10.45		12+3	Dr Vamshikrishna Malyla	Understanding the role of mitochondrial targeted antioxidants for bushfire induced airway inflammation	
10.45-11.15 Morning Tea 30					
11.15-11.45	Bronchiectasis and airway disease	25+5	Prof. Huib Kerstjen	Bronchodilator and anti-inflammatory effects of anticholinergic agents. From bench to bedside?	
11.45-12.15		25+5	Prof Lucy Morgan	A cure for bronchiectasis- on the Horizon or under the rainbow?	
12.15-12.30		12+3	Prof Peter Middleton	Cystic Fibrosis modulator therapy can reverse cystic bronchiectasis	
12.30-12.45		12+3	Ms Susan Muiser	Effects of Glycopyrronium added to Indacaterol/Mometasone on allergen-induced inflammation and airway responses in asthma	
12.45-1.00		12+3	A/Prof Greg Katsoulotos		
1.00-2.00 Lunch 60					
2.00-2.50	Multi-omics of respiratory disease	45+5	Prof Francesca Polverino	Integration of multiomics: novel tools to dissect COPD	
2.50-3.05		12+3	Mr Hao Chen	Unravelling New Pathogenesis of Cigarette Smoke-Induced COPD: Insights from Spatial Transcriptomics	
3.05-3.20		12+3	Mr Rashad Mahbub	Uncovering unique gene signature for COPD through integrating human airway datasets	
3.20-3.35		12+3	Ms Tayyaba Sadaf	Whole-genome CRISPR loss-of-function screen to identify protective factors against cigarette smoke	
3.35-4.05 Afternoon tea					